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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Lactobacillus rhamnosus GG and maintenance of normal defecation during 
antibiotic treatment pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Fuko Pharma Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Finland, the EFSA Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Lactobacillus 
rhamnosus GG and maintenance of normal defecation during antibiotic treatment. The food constituent, 
Lactobacillus rhamnosus GG, which is the subject of the health claim, is sufficiently characterised. The claimed 
effect proposed by the applicant is “help to maintain normal defecation during antibiotic treatment” and the target 
population proposed by the applicant is “healthy outpatient adults and children on oral antibiotic treatment”. 
Maintenance of normal defecation during antibiotic treatment is a beneficial physiological effect. The Panel notes 
that the information submitted from five out of seven human intervention studies is insufficient to allow a full 
scientific evaluation, and that these studies have important methodological limitations. No conclusions could be 
drawn from these studies for the scientific substantiation of the claim. The remaining two human intervention 
studies, from which conclusions could be drawn for the scientific substantiation of the claim, did not show an 
effect of Lactobacillus rhamnosus GG on the incidence of diarrhoea resulting from antibiotic treatment. The 
Panel concludes that a cause and effect relationship has not been established between the consumption of 
Lactobacillus rhamnosus GG and maintenance of normal defecation during antibiotic treatment. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Fuko Pharma Ltd, submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion 
on the scientific substantiation of a health claim related to Lactobacillus rhamnosus GG and 
maintenance of normal defecation during antibiotic treatment. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The Panel considers that the food constituent, Lactobacillus rhamnosus GG, which is the subject of 
the health claim, is sufficiently characterised.  
The claimed effect proposed by the applicant is “help to maintain normal defecation during antibiotic 
treatment”. The target population proposed by the applicant is “healthy outpatient adults and children 
on oral antibiotic treatment”. In the context of the studies provided for the scientific substantiation of 
this claim, the Panel notes that the target population is adults and children under antibiotic treatment. 
The Panel considers that maintenance of normal defecation during antibiotic treatment is a beneficial 
physiological effect. 
The applicant identified seven human intervention studies and four meta-analyses of human 
intervention studies as being pertinent to the health claim. 
Three out of the four intervention studies, which were conducted in adults, investigated the effect of 
L. rhamnosus GG on the occurrence of antibiotic-associated side-effects including diarrhoea in 
asymptomatic patients under Helicobacter pylori eradication therapy. Upon a request by EFSA for 
clarification, the applicant indicated that diarrhoea was defined as “persistent (at least three days) 
increased frequency or decreased consistency of bowel movements with respect to baseline” as 
assessed by the study subjects. The Panel notes that the information submitted for these three studies, 
both in the application and following a request for clarification by EFSA, was insufficient (e.g. 
imprecise criteria for self-diagnosed diarrhoea episodes, insufficient description of the statistical 
analyses, and insufficient description of the study population) to allow a full scientific evaluation. In 
addition, the three studies have important methodological limitations (e.g. multiple comparisons were 
not considered in the data analysis, and open label design for one study based on self-reported 
outcomes). The Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the claim.  
The fourth intervention study, which was conducted in adults under erythromycin therapy, 
investigated the effect of L. rhamnosus GG on several symptoms including diarrhoea. The Panel notes 
that the information submitted for this study, both in the application and following a request for 
clarification by EFSA, is insufficient (e.g. insufficient description of the study population, no 
information on the validation of the procedure used for reporting symptoms, and results regarding the 
incidence of diarrhoea and the number of defecations per day were not reported) to allow a full 
scientific evaluation, and that this study has a high risk of bias due to important methodological 
limitations (e.g. no definition of diarrhoea, and inappropriate statistical analysis for the study design). 
The Panel considers that no conclusions can be drawn from this study for the scientific substantiation 
of the claim.  
One out of three double-blind, placebo-controlled intervention studies, which were conducted in 
children, investigated the incidence of diarrhoea in 167 children who received capsules containing 
L. rhamnosus GG or placebo during an oral antibiotic treatment for acute respiratory infections. The 
primary outcome was the occurrence of diarrhoea, which was defined as at least three watery or loose 
stools per day for a minimum of two consecutive days, during the first two weeks after the beginning 
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of the antibiotic treatment. The Panel notes that results for the intention-to-treat analysis were not 
provided, and that this study reported a borderline significant effect of L. rhamnosus GG on the 
incidence of diarrhoea within two weeks of antibiotic therapy in the population of completers only. 
The Panel also notes the high dropout rate, and the lack of information on the number of subjects who 
dropped out and experienced diarrhoea. The Panel considers that this study does not show an effect of 
L. rhamnosus GG on the incidence of diarrhoea in children during antibiotic treatment. 
In a single centre, double-blind, placebo-controlled study, 83 hospitalised H. pylori-positive children 
were randomised to receive a 7-day H. pylori eradication therapy plus capsules containing 
L. rhamnosus GG or placebo during the duration of the H. pylori eradication therapy. The primary 
outcome of the study was the rate of H. pylori eradication. The secondary outcomes were the 
proportion of patients with treatment-associated diarrhoea, defined as three or more loose or watery 
stools per day for a minimum of 48 hours occurring during and/or up to two weeks after the end of the 
antibiotic therapy; and other gastrointestinal side effects during H. pylori eradication therapy. The risk 
of treatment-associated diarrhoea was not significantly different between groups. The Panel notes that 
this study does not show an effect of L. rhamnosus GG on the incidence of diarrhoea during antibiotic 
treatment for H. pylori eradication, that the dose of L. rhamnosus GG used in the study was one 
logarithmic unit lower than that proposed in the conditions of use for this claim, and that power 
calculations were not performed. 
A randomised, double-blind, placebo-controlled study investigated the effect of L. rhamnosus GG on 
the occurrence of diarrhoea in children on antibiotic treatment for acute infection of the upper or 
lower respiratory tract, urinary tract, soft tissues, or skin. Upon a request by EFSA for clarification, 
the applicant indicated that diarrhoea was defined as the presence of at least two liquid stools per day 
on at least two “observation periods” during the course of the study. The Panel notes that the 
information submitted in relation to this study, both in the application and following a request for 
clarification by EFSA, is insufficient (e.g. unclear description of the methods used for the statistical 
analysis of the data, poor data reporting, and imprecise definition of diarrhoea episodes) to allow a 
full scientific evaluation, and that the study has a high risk of bias due to important methodological 
limitations (e.g. the use of “observation periods” to define the presence of diarrhoea for data analysis 
was not scientifically justified). The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim. 
The Panel considers that the meta-analyses provided by the applicant cannot be used for the scientific 
substantiation of the claim as they included only two studies, from one of which no conclusions could 
be drawn for the scientific substantiation of the claim on L. rhamnosus GG, or they included studies 
conducted with different strains of L. rhamnosus rather than with L. rhamnosus GG. 
In weighing the evidence, the Panel considers that the only two human intervention studies from 
which conclusions could be drawn did not show an effect of Lactobacillus rhamnosus GG on the 
incidence of diarrhoea resulting from antibiotic treatment. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus rhamnosus GG and maintenance of normal defecation during antibiotic 
treatment. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 21/12/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 The scientific evaluation procedure started on 28/01/2013. 
 On 28/02/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 06/03/2013 and restarted on 21/03/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 26/03/2013, EFSA received the requested information (which was made available to 
EFSA in electronic format on 20/03/2013). 
 During its meeting on 30/05/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Lactobacillus 
rhamnosus GG and maintenance of normal defecation during antibiotic treatment. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Lactobacillus rhamnosus GG and 
maintenance of normal defecation during antibiotic treatment. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of Lactobacillus rhamnosus GG, a positive assessment of its safety, nor a decision on 
whether Lactobacillus rhamnosus GG is, or is not, classified as a foodstuff. It should be noted that 
such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Fuko Pharma Ltd, Microkatu 1, PO Box 1188, 70211 Kuopio, 
Finland 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent that is the subject of the health claim is Lactobacillus 
rhamnosus GG (ATCC n. 53103). 
Health relationship as claimed by the applicant 
According to the applicant, the health claim refers to the ability of Lactobacillus rhamnosus GG 
(ATCC n. 53103) to help to maintain normal defecation during antibiotic treatment. The applicant 
states that the mechanisms of action can result from different factors related to gut microbial ecology 
and interaction between the bacteria and host: the microbes abilities to digest food and compete for 
nutrients with pathogens, to alter local pH to create an unfavourable local environment for pathogens, 
to produce bacteriocins to inhibit or kill pathogens, to scavenge superoxide radicals, to down-regulate 
the expression of virulence factors required for pathogenesis, to enhance the immunity by interacting 
with the immune system, to stimulate epithelial mucin production, to enhance intestinal barrier 
function, to compete for adhesion with pathogens and/or their abilities to modify pathogen-derived 
toxins. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Lactobacillus rhamnosus GG 
for maintaining normal defecation during oral antibiotic treatment”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily dose of 2-4 x 10
10
 CFU Lactobacillus rhamnosus GG (ATCC 
n. 53103) to be consumed as 2-4 capsules per day, divided into two doses per day, during oral 
antibiotic treatment. The target population is healthy outpatient adults and children on oral antibiotic 
treatment. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is Lactobacillus rhamnosus GG.  
The strain L. rhamnosus GG has been identified and characterised at species and strain level using 
both phenotypic and genotypic methods. The Panel notes that the culture collection number from the 
American Type Culture Collection (ATCC 53103) is given. The genome sequence of L. rhamnosus 
GG has been published by Kankainen et al. (2009). 
Data on the manufacturing process, formulation into capsules, safety and stability were provided.  
The Panel considers that the food constituent, Lactobacillus rhamnosus GG, which is the subject of 
the health claim, is sufficiently characterised. 
Lactobacillus rhamnosus GG and maintenance of normal defecation 
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2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “help to maintain normal defecation during antibiotic 
treatment”. The target population proposed by the applicant is “healthy outpatient adults and children 
on oral antibiotic treatment”. In the context of the studies provided for the scientific substantiation of 
this claim, the Panel notes that the target population is adults and children under antibiotic treatment.  
The outcome measures proposed by the applicant to assess the claimed effect include absence of 
diarrhoea, defined as decreased stool consistency and increased stool frequency, duration of 
diarrhoea, and absence of constipation.  
Following a request by EFSA, the applicant clarified that the claimed effect relates to a reduction in 
the incidence of diarrhoea episodes during antibiotic treatment in subjects without diarrhoea at 
recruitment.  
The Panel considers that maintenance of normal defecation during antibiotic treatment is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed/Medline and in the Cochrane Database of 
Systematic Reviews in May 2012 using the search terms “Lactobacillus GG AND antibiotic”, 
“Lactobacillus GG” and “antibiotic-associated-diarrhea AND probiotics”, in order to identify studies 
on the effects of L. rhamnosus GG on defecation during antibiotic treatment. Studies with defecation 
as an outcome but unrelated to antibiotic treatment were excluded. 
Based on the search criteria described above, the applicant identified seven human intervention 
studies (Siitonen et al., 1990; Arvola et al., 1999; Vanderhoof et al., 1999; Armuzzi et al., 2001a, b; 
Cremonini et al., 2002; Szajewska et al., 2009) and four meta-analyses of human intervention studies 
(Szajewska et al., 2006; Johnston et al., 2006, 2007, 2011) as being pertinent to the health claim. 
The Panel notes that four of the human intervention studies (Armuzzi et al., 2001a, b; Cremonini et 
al., 2002; Szajewska et al. 2009) were conducted in asymptomatic patients undergoing eradication 
therapy, consisting of antibiotics plus proton pump inhibitors (PPI), for H. pylori infection. The Panel 
notes that diarrhoea and constipation are possible side effects of PPI. However, given that the 
incidence of these side effects in relation to treatment with PPI is comparable, and that such effects of 
PPI may have been equally distributed among study groups, the Panel considers that results from 
studies in patients undergoing eradication therapy for H. pylori can be used for the scientific 
substantiation of a claim on maintenance of normal defecation during antibiotic treatment. 
The Panel also notes that, whereas in the studies by Szajewska et al. (2009) and by Vanderhoof et al. 
(1999) consumption of food products containing live microorganisms other than the study products 
was not allowed to minimise confounding, information on background consumption of live 
microorganisms during the intervention is lacking in the remaining studies.  
Human intervention studies in adults  
Four human intervention studies on the effects of L. rhamnosus GG during antibiotic treatment were 
conducted in adults (Siitonen et al., 1990; Armuzzi et al., 2001a, b; Cremonini et al., 2002).  
In the double-blind, placebo-controlled study by Armuzzi et al. (2001a), 60 H. pylori-positive 
asymptomatic (i.e. absence of gastrointestinal symptoms) volunteers (male/female: 25/35; age 
28-52 years) were recruited among the hospital staff and were randomised to receive a 7-day H. pylori 
eradication therapy (rabeprazole, clarythromicin, tinidazole) plus a freeze-dried powder containing 
L. rhamnosus GG (12 x 10
9
 CFU/day) (n = 30) or an identical placebo without L. rhamnosus GG 
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(n = 30) for 14 days (i.e. during and the week after eradication therapy). At the end of the eradication 
therapy week and the last day of the three subsequent weeks, each subject reported the presence of 
symptoms (taste disturbance, loss of appetite, nausea, vomiting, stomach pain, bloating, diarrhoea, 
constipation, skin rash) and the severity of each symptom (mild, moderate, severe) through the self-
reported questionnaire which was designed for evaluating H. pylori eradication therapy side-effects 
(de Boer et al., 1996), and which was modified to include bloating and constipation, as clarified by 
the applicant upon a request by EFSA. Subjects also provided an overall judgment of tolerability 
based on a five point scale. For each symptom, the relative risk (RR) and 95 % confidence interval 
(CI) was calculated.  
In an open label study by the same research group (Armuzzi et al., 2001b), 120 H. pylori-positive 
asymptomatic (i.e. absence of dyspeptic symptoms) volunteers (male/female: 54/66; age 26-48 years) 
were recruited among hospital staff and randomised to receive a 7-day H. pylori eradication therapy 
(pantoprazole, clarithromycin, tinidazole) with or without a freeze-dried powder containing 
L. rhamnosus GG. This study investigated the same outcomes as the study by Armuzzi et al. (2001a) 
and at the same time points. The Panel notes that open label studies, as in this study, have a high risk 
of bias for self-reported outcomes. 
In a double-blind, placebo-controlled study by the same research group (Cremonini et al., 2002), a 
total of 97 H. pylori-positive asymptomatic (i.e. absence of gastrointestinal symptoms) volunteers 
(male/female: 43/54; age 18-61 years) were enrolled. Subjects were excluded if they had any 
symptoms or consumed any “drug associated with gastro-intestinal side effects” during the three week 
run-in period. After the run-in period, 85 subjects under a 7-day H. pylori eradication therapy 
(rabeprazole, clarythromicin, tinidazole) were randomised to one of the following four arms: a freeze-
dried powder containing L. rhamnosus GG (12 x 10
9
 CFU/day) (group I; n = 21), or a Saccharomyces 
boulardii preparation (10 x 10
9
 CFU/day) (group II; n = 22), or a combination of Lactobacillus 
acidophilus and Bifidobacterium lactis (10 x 10
9
 CFU/day) (group III; n = 21), or placebo (identical 
pack as for the treatments) (group IV; n = 21). The study products were consumed twice a day during 
the week of the H. pylori eradication therapy and the week afterwards. This study investigated the 
same outcomes as the studies by Armuzzi et al. (2001a, b) and at the same time points. The authors 
claimed that a total sample size of 73 subjects was calculated as appropriate to detect a difference of 
20 % in symptom occurrence between active treatment and placebo groups, assuming an expected 
incidence of any side effect in 25 % of subjects treated with antibiotics, with an 80 % power to detect 
differences and a two-sided  of 0.05. Considering the four intervention arms in this study, it is 
unclear to the Panel how the total sample of 73 subjects needed was calculated.  
The Panel noted that in the studies by Armuzzi et al. (2001a, b) and by Cremonini et al. (2002), 
diarrhoea episodes were not defined in the publications nor in the questionnaire by Boer et al. (1996), 
that the primary outcome was not identified and power calculations were not performed except for the 
study by Cremonini et al. (2002), that multiple comparisons were not taken into account in the data 
analyses, and that baseline characteristics of the subjects recruited were not reported. Upon a request 
by EFSA for clarification on these points, the applicant indicated that diarrhoea was defined as 
“persistent (at least three days) increased frequency or decreased consistency of bowel movements 
with respect to baseline” as assessed by the study subjects, that the primary outcome of these studies 
was the occurrence of antibiotic-associated side-effects, that no power calculations were performed 
for two of the studies (Armuzzi et al., 2001a, b), that adjustments for multiple comparisons were not 
considered, and that, although the applicant stated that no significant differences were observed 
between intervention and control groups in any of the studies at baseline, baseline characteristics of 
subjects were not available for these studies.   
The Panel notes that the additional information submitted in relation to these studies (Armuzzi et al., 
2001a, b; Cremonini et al., 2002) upon a request by EFSA is insufficient to allow a full scientific 
evaluation (e.g. imprecise criteria for self-diagnosed diarrhoea episodes, insufficient description of the 
statistical analyses, and insufficient description of the study population). In addition, the Panel notes 
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that these studies have important methodological limitations (e.g. multiple comparisons were not 
considered in the data analysis, and open label design for one study based on self-reported outcomes 
(Armuzzi et al., 2001b)). The Panel considers that no conclusions can be drawn from these studies for 
the scientific substantiation of the claim.  
In the study by Siitonen et al. (1990), 16 male subjects (age 18-24 years) were randomly assigned to 
receive erythromycin acistrate plus a yogurt fermented with Streptococcus thermophilus and 
Lactobacillus bulgaricus and pasteurised afterwards, and then either supplemented with L. rhamnosus 
GG (5 x 10
9
 CFU/day) (n = 8) or non-supplemented (placebo; n = 8) for one week. Participants were 
invited to report symptoms such as diarrhoea, stomach pain and nausea, as well as the number of 
defecations per day and faecal volume, by completing daily records and during an interview with a 
physician before and after the study. The results of observations on the side effects were analysed 
statistically using the Chi-square and student’s t-tests. The Panel notes that baseline characteristics of 
the study population were not reported, that no power calculations were performed, that no 
information on the validation of the procedure used for reporting symptoms was provided, that 
diarrhoea was not defined, that results regarding the incidence of diarrhoea and the number of 
defecations per day were not reported, and that the statistical analysis is inappropriate for the study 
design (e.g. multiple comparisons were not considered). Following a request for clarification by 
EFSA, no further information was provided. The Panel notes that the information submitted in 
relation to this study is insufficient (e.g. insufficient description of the study population, no 
information on the validation of the procedure used for reporting symptoms, and results regarding the 
incidence of diarrhoea and the number of defecations per day were not reported) to allow a full 
scientific evaluation and that the study has a high risk of bias due to important methodological 
limitations (e.g. no definition of diarrhoea, and inappropriate statistical analysis for the study design). 
The Panel considers that no conclusions can be drawn from this study for the scientific substantiation 
of the claim.  
Human intervention studies in children 
Three human intervention studies on the effects of L. rhamnosus GG during antibiotic treatment were 
conducted in children (Arvola et al., 1999; Vanderhoof et al., 1999; Szajewska et al., 2009). 
In a randomised, double-blind, placebo-controlled study, Arvola et al. (1999) investigated the 
incidence of diarrhoea in 167 children who received capsules containing L. rhamnosus GG 
(4 x 10
10
 CFU/day) (n = 89) or placebo (microcrystalline cellulose) (n = 78) during an oral antibiotic 
treatment (7-10 days) for acute respiratory infections. Exclusion criteria were antibiotic treatment 
during the previous three months, gastrointestinal disorders, and need for intravenous antibiotic 
treatment. All subjects except five (hospitalised) were outpatients. The primary outcome was 
diarrhoea during the first two weeks after the beginning of the antibiotic treatment. Diarrhoea was 
defined as at least three watery or loose stools per day for a minimum of two consecutive days. 
Parents kept daily symptom diaries and recorded stool frequency and consistency (solid, loose, 
watery) at home for three months; with respect to diarrhoea, faecal samples were taken for viral and 
bacterial analyses. Secondary outcomes were the activities of faecal urease, β-glucuronidase, and 
β-glucosidase. A total of 28 (31 %) and 20 (26 %) subjects from the L. rhamnosus GG and placebo 
groups, respectively, were lost at follow-up or discontinued the study; one reason, among other 
unspecified reasons given, was the difficulty in the transportation of the study samples. No 
information on the number of subjects who dropped out and experienced diarrhoea in the intervention 
and in the control groups was provided in the application or following a request for clarification by 
EFSA. Data analyses were undertaken in the sample of completers only (n = 119; mean age 4.5 years; 
age range from two weeks to 12.8 years; 72 % < 6 years), who were comparable at baseline regarding 
mean age, clinical diagnosis, antibiotics, history of antibiotic use, and mode of day care. Intention-to-
treat (ITT) analyses were not reported in the publication and were not provided upon a request by 
EFSA. In the population of completers, the incidence of diarrhoea within two weeks of antibiotic 
therapy was 5 % (3/61) in the L. rhamnosus GG group and 16 % (9/58) in the placebo group 
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(X2 = 3.82; p = 0.05). The treatment effect (95 % CI) of L. rhamnosus GG was -11 % (-21 %-0 %). 
The severity of diarrhoea (mean stool frequency five times per day; range: 3-6) and the duration of 
diarrhoea (mean 4 days; range: 2-8) were not different between groups. In diarrhoeal episodes, the 
viral and bacterial analyses were positive for Clostridium difficile in two cases (one in both groups) 
and Norwalk-like calicivirus in three cases (one in the intervention group and two in the placebo 
group). The Panel notes that this study reported a borderline significant effect of L. rhamnosus GG on 
the incidence of diarrhoea during antibiotic treatment in the population of completers only. However, 
the Panel also notes the high dropout rate, the lack of information on the number of subjects who 
dropped out and experienced diarrhoea, and that results for the ITT analysis were not provided. The 
Panel considers that this study does not show an effect of L. rhamnosus GG on the incidence of 
diarrhoea in children during antibiotic treatment. 
In the single centre, double-blind, placebo-controlled study by Szajewska et al. (2009), 83 hospitalised 
H. pylori-positive children (male/female: 39/44; age 5-17 years) were randomised to receive a 7-day 
H. pylori eradication therapy (amoxicillin, clarithromycin, omeprazole) plus capsules containing 
L. rhamnosus GG (2 x 10
9
 CFU/day) (n = 44) or placebo (maltodextrine) (n = 39) during the duration 
of the H. pylori eradication therapy. H. pylori infection was confirmed by two of the three following 
tests: the 
13
C-urea breath test (UBT), histopathology (haematoxylin and eosin staining), the rapid 
urease test. Exclusion criteria were acute or chronic gastrointestinal disease, current use of antiacids, 
and use of antibiotics in the previous seven days. The primary outcome of the study was the rate of 
H. pylori eradication, which had to be confirmed by a negative UBT at least four weeks after 
treatment. The secondary outcomes were the proportion of patients with treatment-associated 
diarrhoea, defined as three or more loose or watery stools per day for a minimum of 48 hours 
occurring during and/or up to two weeks after the end of the antibiotic therapy; any gastrointestinal 
side effects, including abdominal pain, nausea, vomiting, constipation, flatulence, taste disturbance, or 
loss of appetite, during H. pylori eradication therapy; the need for discontinuation of the H. pylori 
eradication therapy. Each patient received forms/diaries to record the frequency of side effects and 
any symptoms they considered important; the forms/diaries were completed at study entry, at day 7 
(end of treatment), at day 21 (two weeks after treatment), and at four to six weeks after treatment. The 
children were evaluated clinically at study entry, at day 7, at day 21, and at 4 to 6 weeks after 
enrolment. A total of 17 children (10 in the treatment group and 7 in the placebo group) were 
excluded from the analysis because of lack of diaries and/or UBT at follow-up. The Panel notes that 
exclusion of children with no UBT at follow-up is not appropriate for the analysis of the outcome 
measure (risk of antibiotic-associated diarrhoea) of interest in relation to this claim. The risk of 
antibiotic-associated diarrhoea was not significantly different between groups (L. rhamnosus GG 
group 2/34 (6 %) vs placebo group 6/30 (20 %), RR = 0.3, 95 % CI 0.07–1.2). The Panel notes that 
this study does not show an effect of L. rhamnosus GG on the incidence of diarrhoea during antibiotic 
treatment for H. pylori eradication in children. The Panel also notes that the dose of L. rhamnosus GG 
used in the study was one logarithmic unit lower than that proposed in the conditions of use for this 
claim, and that power calculations were not performed. 
In a randomised, double-blind, placebo-controlled study (Vanderhoof et al., 1999), 202 children (age 
from 6 months to 10 years) recruited from a private primary care paediatric practice on a 10-day 
antibiotic treatment for acute infection of the upper or lower respiratory tract, urinary tract, soft 
tissues, or skin were randomised to receive capsules containing inulin (325 mg) plus L. rhamnosus 
GG (1 x 10
10
 CFU/day if weight < 12 kg or 2 x 10
10
 CFU/day if weight > 12 kg ) (n = 100) or placebo 
(inulin, 325 mg; n = 102).  
It was reported that 202 children were randomised based on power calculations (  = 0.05 and 
0.80 power), but no information (e.g. primary outcome, target difference between groups, variability 
of the selected outcome) was provided on how these calculations were performed. Children with any 
chronic disease, serious acute infection, or diarrhoea at the time of antibiotic initiation were excluded 
from this study. Parents were contacted within 24 hours of initial enrolment for baseline data 
collection by one of the investigators, and subsequently every three days until antibiotic courses were 
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completed or diarrhoea ceased. Parents were asked to complete a questionnaire reporting on gastro-
intestinal events. At each contact with the parents, stool frequency (number of stools passed during a 
24-hour period) and consistency (based on eight line drawings depicting stools varying from watery to 
hard and dry) were assessed and graded numerically. Diarrhoea was defined as the presence of at least 
two liquid stools per day on at least two “observation periods” during the course of this study. Upon a 
request for clarification by EFSA, the applicant indicated that one “observation period” consisted of 
3-4 days during the study period (i.e. days 1-4, days 4-7 and days 7-10 being the 1
st
, 2
nd
 and 3
rd
 
observation periods, respectively), and that the definition of diarrhoea included that at least two liquid 
stools per day were observed at least in two of these periods, e.g. diarrhoea was continuous or was 
repeated at least twice. The Panel notes that diarrhoea episodes were imprecisely defined (i.e. the 
number of consecutive days with at least two liquid stools per day was not specified) and that the 
subdivision of the whole study period into “observation periods” consisting of three days each to 
define the presence of diarrhoea for data analysis was not scientifically justified. The presence or 
absence of visible blood content in the stool, abdominal pain, nausea, vomiting, bloating, and appetite 
suppression were also assessed. If present, the intensity of abdominal pain was recorded on a visual 
analog scale. The Panel notes that the primary outcome of the study was not identified in the 
publication, and that a large number of outcome measures were assessed.  
A total of 14 children failed to complete the study because of antibiotic non-compliance or inability of 
the investigators to contact the parents at the assigned follow-up time. None of the participants failed 
to complete the 10-day course of antibiotics because of a change in stool consistency or frequency. 
Statistical analyses were carried out in the population of completers only. The Panel notes that 
reasons for dropping out are given. It was reported that stool consistency scores and stool frequency 
were analysed by a mixed design, groups observation point, analysis of variance, and that 
Newman-Keuls pairwise comparisons were performed. It was also reported that Chi-squared analysis 
was performed to evaluate the occurrence of the stool consistency score of < 4 on either day 7 or day 
10 of the observation period. The Panel notes that the description of the methods used for the 
statistical analysis of the data is unclear and insufficient for a scientific evaluation. No further 
information, except for the p-values of a Chi-squared analysis in relation to the incidence of 
diarrhoea, was provided upon a request by EFSA. 
The Panel notes that the additional information submitted in relation to this study in response to a 
request by EFSA is insufficient (e.g. unclear description of the methods used for the statistical 
analysis of the data, poor data reporting, and imprecise definition of diarrhoea episodes) to allow a 
full scientific evaluation, and that the study has a high risk of bias due to important methodological 
limitations (e.g. the use of “observation periods” to define the presence of diarrhoea for data analysis 
was not scientifically justified). The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim. 
Meta-analyses of human intervention studies in children 
The meta-analyses by Johnston et al. (2006) and Szajewska et al. (2006) included subgroup analyses 
of two studies using L. rhamnosus GG (Arvola et al., 1999; Vanderhoof et al., 1999) which have been 
described above. The Panel notes that subgroup analyses in both of these meta-analyses only included 
two studies, one of which was the study by Vanderhoof et al. (1999) which provided insufficient data 
for the scientific substantiation of the claim. The Panel considers that no conclusions can be drawn 
from these meta-analyses for the scientific substantiation of the claim. 
The meta-analysis by Johnston et al. (2008) reported the results of an analysis on the effects of 
L. rhamnosus GG (studies by Arvola et al. (1999) and Vanderhoof et al. (1999)) combined with other 
strains of Lactobacillus rhamnosus on the incidence of diarrhoea during antibiotic use. The meta-
analysis by Johnston et al. (2011) included the studies by Arvola et al. (1999), Szajewska et al. (2009) 
and Vanderhoof et al. (1999), which were considered pertinent by the applicant and have been 
described above, in addition to intervention studies using other strains and strain combinations. The 
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Panel considers that these meta-analyses which combine the results from studies conducted with 
different strains of L. rhamnosus cannot be used for the scientific substantiation of a claim on 
L. rhamnosus GG.  
In weighing the evidence, the Panel considers that the two human intervention studies (Arvola et al., 
1999; Szajewska et al., 2009) from which conclusions could be drawn for the scientific substantiation 
of the claim did not show an effect of Lactobacillus rhamnosus GG on the incidence of diarrhoea 
resulting from antibiotic treatment. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus rhamnosus GG and maintenance of normal defecation during antibiotic 
treatment. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, Lactobacillus rhamnosus GG, which is the subject of the health claim, 
is sufficiently characterised. 
 The claimed effect proposed by the applicant is “help to maintain normal defecation during 
antibiotic treatment”. The target population proposed by the applicant is “healthy outpatient 
adults and children on oral antibiotic treatment”. Maintenance of normal defecation during 
antibiotic treatment is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Lactobacillus rhamnosus GG and maintenance of normal defecation during antibiotic 
treatment. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Lactobacillus rhamnosus GG and maintenance of normal defecation 
during antibiotic treatment pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial 
No: 0372_FI). December 2012. Submitted by Fuko Pharma Ltd. 
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GLOSSARY/ABBREVIATIONS 
ATCC  American Type Culture Collection 
CI  Confidence interval 
CFU  Colony forming units 
ITT  Intention-to-treat 
PPI  Proton pump inhibitors 
RR  Relative risk  
UBT  
13
C-urea breath test 
